- Home
- NBY vs SCNI Comparison
NBY vs SCNI Comparison
Compare NBY & SCNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBY
- SCNI
- Stock Information
- Founded
- NBY 2000
- SCNI 2003
- Country
- NBY United States
- SCNI Israel
- Employees
- NBY N/A
- SCNI N/A
- Industry
- NBY
- SCNI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NBY
- SCNI Health Care
- Exchange
- NBY Nasdaq
- SCNI Nasdaq
- Market Cap
- NBY 2.8M
- SCNI 3.1M
- IPO Year
- NBY 2007
- SCNI N/A
- Fundamental
- Price
- NBY $0.73
- SCNI $3.51
- Analyst Decision
- NBY Strong Buy
- SCNI
- Analyst Count
- NBY 1
- SCNI 0
- Target Price
- NBY $0.85
- SCNI N/A
- AVG Volume (30 Days)
- NBY 492.7K
- SCNI 8.1K
- Earning Date
- NBY 11-07-2024
- SCNI 11-22-2024
- Dividend Yield
- NBY N/A
- SCNI N/A
- EPS Growth
- NBY N/A
- SCNI N/A
- EPS
- NBY N/A
- SCNI 8.20
- Revenue
- NBY $13,844,000.00
- SCNI $452,000.00
- Revenue This Year
- NBY N/A
- SCNI N/A
- Revenue Next Year
- NBY $17.31
- SCNI N/A
- P/E Ratio
- NBY N/A
- SCNI $0.43
- Revenue Growth
- NBY 15.40
- SCNI N/A
- 52 Week Low
- NBY $0.07
- SCNI $2.23
- 52 Week High
- NBY $6.30
- SCNI $8.92
- Technical
- Relative Strength Index (RSI)
- NBY 63.10
- SCNI 52.75
- Support Level
- NBY $0.65
- SCNI $3.41
- Resistance Level
- NBY $0.78
- SCNI $3.80
- Average True Range (ATR)
- NBY 0.06
- SCNI 0.18
- MACD
- NBY 0.01
- SCNI -0.00
- Stochastic Oscillator
- NBY 83.07
- SCNI 36.42
About NBY NovaBay Pharmaceuticals Inc.
NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically eyecare and skincare products. Its product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is laboratory tested to have broad antimicrobial properties as it removes foreign material including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available directly to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease. It has two reportable segments: Eyecare and Wound Care and Skincare.
About SCNI Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company focused on developing, manufacturing and commercializing products for the prevention and treatment of infectious diseases and other illnesses. It has executed eight clinical trials in seven countries, around 12,400 participants in the Phase 3 trial of its vaccine candidate and has built a GMP biologics manufacturing facility for biopharmaceutical products. The company is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with a nanosized antibody (NanoAb) pipeline.